识别和验证血管生成相关的基因,重塑瘤微环境和抑制胃癌中免疫治疗反应
Guiyuan Li1, Zhe Li2, Jing Shen3
1Department of Oncology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Gene
|July 27, 2024
概括
这项研究开发了一种五基因模型,预测胃癌存活率和免疫治疗反应. 低风险患者对抗PD1治疗的结果更好,反应率更高,FGF1被确定为关键的预后标.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 血管新生对于瘤微环境重塑和胃癌免疫疗法反应至关重要.
- 需要用于胃癌预后和治疗反应的预测模型.
研究的目的:
- 建立基于血管生成相关基因的预后模型,用于胃癌.
- 评估模型预测整体存活率和免疫治疗反应的能力.
主要方法:
- 使用公共数据库来识别五个基因签名 (FGF1,GRB14,PAK3,PDGFRA,PRKD1).
- 进行了生存分析,基因本体学 (GO),基因组丰富分析 (GSEA),CIBERSORT和TIMER分析.
- 使用组织微阵列 (TMA) 和体内小鼠模型验证的结果.
主要成果:
- 这种五基因模型有效地预测了胃癌患者的整体存活率.
- 高风险患者表现出免疫抑制瘤微环境和对抗PD1治疗的反应较低.
- 过度表达FGF1与预后不佳和免疫细胞透相关;抑制FGF1抑制了瘤生长,并在小鼠中增强了抗PD1功效.
结论:
- 一个新的五种血管生成相关基因模型可以预测胃癌的存活率和免疫治疗反应.
- FGF1是一种潜在的预后生物标志物和治疗点,用于改善胃癌免疫疗法.
更多相关视频
09:03Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
9.7K
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.4K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
01:27Tumor Immunotherapy
498
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
498
01:24Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K